Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 920 across all filing types
Latest filing 2025-07-04 Director's Dealing
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
treść powiadomienia
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction/transactions referred to in Article 19(1) of the MAR Regulation). It details share transactions (Nabycie - Acquisition) conducted by a person discharging managerial responsibilities ('Dyrektor ds. Finansowych' - CFO) in the company's shares, including specific dates, prices, and volumes. This content directly corresponds to the definition of Director's Dealing (insider trades). Reviewing the definitions: - 10-K, AR, IR are comprehensive financial reports. - ER, MRQ are earnings/quarterly results. - The document explicitly reports personal share transactions by an executive. This matches the definition for Director's Dealing (Code: DIRS).
2025-07-04 Polish
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Content (PL)
Director's Dealing Classification · 99% confidence The document text is very short (565 characters) and explicitly states that the Management Board ('Zarząd') received a notification from the CFO ('Dyrektora ds. Finansowych') regarding a transaction in the company's shares, referencing Article 19(1) of the MAR Regulation. The content details the purchase of 3,300 shares by an executive between April 16, 2025, and July 4, 2025. This directly corresponds to the definition of Director's Dealing (insider trades by executives). The filing type code for this is DIRS.
2025-07-04 Polish
Wykaz akcjonariuszy posiadających na Zwyczajnym Walnym Zgromadzeniu Spółki 26 czerwca 2025 r. co najmniej 5% głosów - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document text explicitly states that the Management Board ('Zarząd spółki') is providing a list of shareholders who held at least 5% of the votes at the Ordinary General Meeting ('Zwyczajnym Walnym Zgromadzeniu Spółki') held on June 26, 2025. This content—reporting the results of shareholder voting percentages from a general meeting—directly matches the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not an AGM presentation (AGM-R), nor is it a general management change announcement (MANG).
2025-07-02 Polish
oświadczenie
Board/Management Information Classification · 98% confidence The document is a formal declaration ('OŚWIADCZENIE') from an individual, Dr. Andrew Galazka, consenting to be nominated and appointed as an independent member of the Supervisory Board ('Rada Nadzorcza') of Captor Therapethics S.A. The declaration includes standard legal affirmations regarding independence, lack of conflicts of interest, and compliance with relevant Polish corporate law (KSH) and EU recommendations regarding non-executive directors. This type of document relates directly to the composition and governance structure of the company's board, fitting the definition of Board/Management Information (MANG). It is not an AGM result (DVA), a general governance report (CGR), or a remuneration disclosure (DEF 14A), but a specific statement required for a management/board appointment.
2025-06-26 Polish
życiorys (PL)
Board/Management Information Classification · 99% confidence The document provided is a biography ('Biografia') of an individual named Dr. Andrew Galazka, detailing his professional experience, education, and board memberships, primarily in the biotech/pharmaceutical sector. This type of biographical information is typically included in materials related to corporate governance, such as proxy statements, annual reports, or materials related to the election or appointment of directors/management. Since the text focuses entirely on the qualifications and background of a key individual, it strongly aligns with the content expected for Board/Management Information (MANG) or potentially Governance Information (CGR). Given the focus on his role as a director and senior advisor, MANG is the most specific fit for announcing or detailing management/board composition.
2025-06-26 Polish
życiorys
Board/Management Information Classification · 95% confidence The document provided is a detailed biography of an individual, Dr. Andrew Galazka, listing his professional experience, education, and current board positions. This type of biographical information is typically included in materials related to corporate governance, such as proxy statements (DEF 14A), annual reports (10-K), or materials related to board appointments/changes. Since the text focuses entirely on the qualifications and history of a board member/executive, it strongly aligns with the content found in Board/Management Information (MANG) or Remuneration Information (DEF 14A). Given that it is a biography rather than a specific announcement of a change (MANG) or a detailed compensation report (DEF 14A), and considering the context of corporate filings, this content is most commonly found as supporting documentation for board composition or director qualifications. MANG (Board/Management Information) is the most appropriate category for a detailed executive biography presented outside of a full annual report.
2025-06-26 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.